Large Algorithm Setting and Validation Study
Start Date
6/3/2026
Completion Date
1/1/2027
Summary
In this pilot study, prospectively acquired clinician-collected and participant-collected vaginal swab specimens will be obtained from up to 1000 individuals with signs and symptoms of vaginitis to develop and validate a bacterial vaginosis diagnostic algorithm and evaluate the performance of the Nanopath assay. The Nanopath assay is an amplification-free molecular test that detects pathogens associated with vaginitis. The performance of the Nanopath assay will be assessed by comparing Nanopath assay results to previously FDA-cleared commercial tests and yeast culture.
Detailed Description
This is an observational, diagnostic study.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Nanopath Vaginitis Assay
BD Max™ Vaginal Panel
Cepheid Xpert® Xpress MVP
Hologic Aptima® BV Assay
Yeast Culture
Conditions
Locations
Segal Trials
North Miami, Florida 33161
United States
LSU-CrescentCare Sexual Health Center
New Orleans, Louisiana 70119
United States